Healthy Skepticism Library item: 18478

Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.

Publication type: Media Release

New research finds no evidence that popular slimming supplements facilitate weight loss
ICO 2010 – The 11 th International Congress on Obesity 2010 July 11
http://web.archive.org/web/20101218212131/http://ico2010.org/documents/6.Weight-losssupplementsrelease-final.pdf

Full text:

New research evaluating the effectiveness of a broad selection of popular
slimming supplements sold in pharmacies and health food shops has found no evidence that any
of them facilitate weight loss beyond the placebo effect.
Two studies presented today (Monday) at the International Congress on Obesity in Stockholm,
Sweden, have found they were no more effective than the fake supplements they were compared
with.
“There are scores of slimming supplements out there claiming weightloss
effects through all sorts
of mechanisms of action. We have socalled
fat magnets, mobilizers and dissolvers, as well as
appetite tamers, metabolism boosters, carb blockers and so on. The market for these is huge, but
unlike for regulated drugs, effectiveness does not have to be proven for these to be sold,” said Dr.
Thomas Ellrott, head of the Institute for Nutrition and Psychology at the University of Göttingen
Medical School, Germany, who lead one of the studies. “Few of these supplements have been
submitted to clinical trials and the landscape of products is always changing, so we need to put
them through rigorous scientific evaluation to determine whether they have any benefit.”
Ellrott’s group tested nine popular supplements 1 against placebo pills in a randomized controlled
trial. The supplements tested included LCarnitine,
polyglucosamine, cabbage powder, guarana
seed powder, bean extract, Konjac extract, fibre pills, sodium alginate formulations and selected
plant extracts.
The researchers bought the supplements from German pharmacies, changed the packaging and
product names to make them look neutral and rewrote the information leaflet inserts to eliminate
the product name from the text. They then gave 189 obese or overweight middleaged
consumers
packages of either fake pills or of one of the nine supplements, each week for eight weeks, in
doses recommended by the manufacturers. Some of the products came with dietary advice, while
others didn’t, so the researchers provided exactly the same advice as that written in the relevant
product leaflets.
Average weight loss was between 1 kg and 2 kg across seven of the products, depending on the
supplement, and was 1.2 kg in the group getting the placebo pills. No statistically significant
difference in weight loss was found for any of those products when compared with the placebo.
“Most previous studies have examined only one product. This is the first to include nine
supplements with different proposed mechanisms of action and we found that not a single product
was any more effective than placebo pills in producing weight loss over the two months of the
study, regardless of how it claims to work,” Ellrott said, adding that if there is an indication for the
1 In Germany some of the tested products are classified as medical devices instead of supplements
use of weightloss
drugs, consumers should opt for regulated obesity drugs with proven effects
(prescription or overthecounter)
instead.
In a second study presented at the congress, Dr. Igho Onakpoya of Peninsula Medical School at
the Universities of Exeter and Plymouth, UK, conducted the first systematic review of all existing
systematic reviews of clinical trials on weight loss supplements. The analysis summarizes the
state of evidence from reviews of studies involving nine popular slimming supplements, including
chromium picolinate, Ephedra, bitter orange, conjugated linoleic acid (CLA), calcium, guar gum,
glucomannan, chitosan and green tea.
“We found no evidence that any of these food supplements studied is an adequate treatment for
reducing body weight,” Onakpoya said. “Annual global sales of dietary supplements are well over
$13 billion. In Western Europe, sales of weightloss
products, excluding prescription medications,
topped £900 million ($1.4 billion) in 2009. The weightloss
industry in North America is worth over
$50 billion and Americans spend over $1.6 billion a year on weightloss
supplements. People
think these supplements are a short cut to weight loss and may spend huge sums of money on
them, but they may end up disappointed, frustrated and depressed if their weight expectations are
not met in the long term.”
Onakpoya said some of the supplements included the study were reported to cause some
adverse effects. However, more rigorous research is needed, he said, as only very few trials have
been of long duration and the number of patients in most of the trials has been small factors
which together limit the conclusions that can be drawn about the effectiveness and safety of such
supplements.
Ellrott’s study was funded by a German consumer issues magazine, while the study by Onakpoya
and colleagues had no particular funding, but Onakpoya’s position is funded by an unrestricted
grant from GlaxoSmithkline, which makes the obesity drug orlistat.